Valeant says it’s making progress halfway through planned turnaround
CEO warns transforming the embattled company is a multi-year process involving incremental steps.
Valeant sells cancer vaccine to China’s Sanpower Group for $819.9M
Quebec pharmaceutical will use the proceeds to permanently repay loan debts.
Valeant writes down Salix value, posts $1.22B loss
Revenue decline blamed on lower product sales, currency exchange rates and divestitures.
Valeant invests $10M in Laval plant upgrades
Enhances manufacturing capabilities and export capacity.
Lawyer pushing Cold fX class action is ‘manufacturing’ case: Valeant
Pharmaceutical firm’s lawyer cites an absence of an easily defined class of complainants.
Cold-fX case should receive class action approval: lawsuit
Makers accused of misleading the public about remedy’s short-term effectiveness.
$425M Dermik buy broadens Valeant’s dermatology business
Valeant Pharmaceuticals International Inc. is adding to its dermatology business with the acquisition of Dermik, a dermatology unit of Sanofi, for $425 million.